Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Search
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
Investigating clinical trial samples to predict how atypical teratoid rhabdoid tumours will respond to treatment
Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
In hospital
Your child will usually need to spend some time in hospital during their treatment. All children and young people diagnosed with cancer are treated in one of the 21 specialist hospital centres across the UK and Ireland.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Optimising therapy in newly diagnosed metastatic Ewing sarcoma
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer